|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Can. 136:E359–E386. 2014.
View Article : Google Scholar
|
|
2
|
van Cutsem E, Nordlinger B and A; ESMO
Cervantes; Guidelines Working Group, : Advanced colorectal cancer:
ESMO Clinical Practice Guidelines for treatment. Ann Oncol. 21
Suppl 5:v93–v97. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bennouna J, Sastre J, Arnold D, Österlund
P, Greil R, van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C,
et al: Continuation of bevacizumab after first progression in
metastatic colorectal cancer (ML18147): A randomised phase 3 trial.
Lancet Oncol. 14:29–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hurwitz HI, Tebbutt NC, Kabbinavar F,
Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D and Tabernero J:
Efficacy and safety of bevacizumab in metastatic colorectal cancer:
Pooled analysis from seven randomized controlled trials.
Oncologist. 18:1004–1012. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pai SG and Fuloria J: Novel therapeutic
agents in the treatment of metastatic colorectal cancer. World J
Gastrointest Oncol. 8:99–104. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spiliopoulou P and Arkenau HT: Rationally
designed treatment for metastatic colorectal cancer: Current drug
development strategies. World J Gastroenterol. 20:10288–10295.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bhartiya D and Scaria V: Genomic
variations in non-coding RNAs: Structure, function and regulation.
Genomics. 107:59–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vychytilova-Faltejskova P, Radova L,
Sachlova M, Kosarova Z, Slaba K, Fabian P, Grolich T, Prochazka V,
Kala Z, Svoboda M, et al: Serum-based microRNA signatures in early
diagnosis and prognosis prediction of colon cancer. Carcinogenesis.
37:941–950. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mishra PJ: MicroRNAs as promising
biomarkers in cancer diagnostics. Biomark Res. 2:192014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cekaite L, Eide PW, Lind GE, Skotheim RI
and Lothe RA: MicroRNAs as growth regulators, their function and
biomarker status in colorectal cancer. Oncotarget. 7:6476–6505.
2016.PubMed/NCBI
|
|
12
|
Boisen MK, Dehlendorff C, Linnemann D,
Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS,
Qvortrup C, Pfeiffer P, et al: Tissue microRNAs as predictors of
outcome in patients with metastatic colorectal cancer treated with
first line capecitabine and oxaliplatin with or without
bevacizumab. PLoS One. 15:e1094302014. View Article : Google Scholar
|
|
13
|
Hansen TF, Carlsen AL, Heegaard NH,
Sørensen FB and Jakobsen A: Changes in circulating microRNA-126
during treatment with chemotherapy and bevacizumab predicts
treatment response in patients with metastatic colorectal cancer.
Br J Cancer. 112:624–629. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carvalho BS and Irizarry RA: A framework
for oligonucleotide microarray preprocessing. Bioinformatics.
26:2363–2367. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
R Development Core Team, . R: a language
and environment for statistical computing. R Foundation for
Statistical Computing; Vienna, Austria: http://www.r-project.org/March 31–2015
|
|
17
|
Smyth GK: Limma: linear models for
microarray dataBioinformatics and Computational Biology Solutions
using R and Bioconductor. Gentleman R, Carey V, Dudoit S, Irizarry
R and Huber W: Springer; New York, NY: pp. 397–420. 2005,
View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vandesompele J, De Preter K, Pattyn F,
Poppe B, van Roy N, De Paepe A and Speleman F: Accurate
normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol.
3:RESEARCH0034. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schee K, Lorenz S, Worren MM, Günther CC,
Holden M, Hovig E, Fodstad O, Meza-Zepeda LA and Flatmark K: Deep
sequencing the microRNA transcriptome in colorectal cancer. PLoS
One. 8:e661652013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Segersten U, Spector Y, Goren Y, Tabak S
and Malmström PU: The role of microRNA profiling in prognosticating
progression in Ta and T1 urinary bladder cancer. Urol Oncol.
32:613–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhi Y, Xie X, Wang R, Wang B, Gu W, Ling
Y, Dong W, Zhi F and Liu Y: Serum level of miR-10-5p as a
prognostic biomarker for acute myeloid leukemia. Int J Hematol.
102:296–303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Benson EA, Skaar TC, Liu Y, Nephew KP and
Matei D: Carboplatin with decitabine therapy, in recurrent platinum
resistant ovarian cancer, alters circulating mirnas concentrations:
A pilot study. PLoS One. 10:e01412792015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gattolliat CH, Uguen A, Pesson M, Trillet
K, Simon B, Doucet L, Robaszkiewicz M and Corcos L: MicroRNA and
targeted mRNA expression profiling analysis in human colorectal
adenomas and adenocarcinomas. Eur J Cancer. 51:409–420. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ozcan O, Kara M, Yumrutas O, Bozgeyik E,
Bozgeyik I and Celik OI: MTUS1 and its targeting miRNAs in
colorectal carcinoma: Significant associations. Tumour Biol.
37:6637–6645. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu Y, Huang Z and Liu Y: Reduced
miR-125a-5p expression is associated with gastric carcinogenesis
through the targeting of E2F3. Mol Med Rep. 10:2601–2608.
2014.PubMed/NCBI
|
|
27
|
Ferracin M, Lupini L, Salamon I, Saccenti
E, Zanzi MV, Rocchi A, da Ros L, Zagatti B, Musa G, Bassi C, et al:
Absolute quantification of cell-free microRNAs in cancer patients.
Oncotarget. 6:14545–14555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Muz B, de la Puente P, Azab F and Azab AK:
The role of hypoxia in cancer progression, angiogenesis,
metastasis, and resistance to therapy. Hypoxia (Auckl). 3:83–92.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Agrawal R, Pandey P, Jha P, Dwivedi V,
Sarkar C and Kulshreshtha R: Hypoxic signature of microRNAs in
glioblastoma: Insights from small RNA deep sequencing. BMC
Genomics. 15:6862014. View Article : Google Scholar : PubMed/NCBI
|
